2021
Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
Shallis RM, Wang R, Bewersdorf JP, Zeidan AM, Davidoff AJ, Huntington SF, Podoltsev NA, Ma X. Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. Therapeutic Advances In Hematology 2021, 12: 20406207211043404. PMID: 35154624, PMCID: PMC8832334, DOI: 10.1177/20406207211043404.Peer-Reviewed Original ResearchChronic phase chronic myeloid leukemiaFrontline tyrosine kinase inhibitorsTyrosine kinase inhibitorsOlder patientsChronic myeloid leukemiaTKI switchingMyeloid leukemiaSecond-generation tyrosine kinase inhibitorsBCR-ABL1 tyrosine kinase inhibitorsTyrosine kinase inhibitor useOlder CML patientsEnd Results-MedicareFavorable safety profileSpecific patient populationsContemporary practice patternsFrontline imatinibTKI choiceGreater comorbidityMost patientsInhibitor usePatient characteristicsWhite patientsDiagnosis yearTKI useCML patients
2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaDecitabine-treated patientsTransfusion independenceRed blood cell transfusion independenceLarge population-based studyOlder AML patientsRBC transfusion independenceEnd Results-MedicarePopulation-based studyStandard of careAgent azacitidineMedian survivalOlder patientsIntensive therapyAML patientsClinical outcomesClinical benefitMyeloid leukemiaMortality riskPatientsAzacitidineDecitabineOlder adultsOne-thirdMeaningful differences
2019
The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia
Podoltsev N, Wang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X. The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia. Blood 2019, 134: 2125. DOI: 10.1182/blood-2019-127563.Peer-Reviewed Original ResearchTherapeutic phlebotomyPopulation-based cohortPV patientsELN guidelinesET patientsPolycythemia veraEssential thrombocythemiaGuideline publicationCelgene CorporationCytoreductive therapyHU useMonthly proportionBoehringer IngelheimLarge population-based cohortAdvisory CommitteeDaiichi SankyoOlder adultsEuropean LeukemiaNet guidelinesEnd Results-MedicareProportion of patientsHealthcare Common Procedure Coding System codesPopulation-based studyPatterns of careTreatment of patientsPart D claimsClinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)
Wang X, Wang R, Zhang C, Zeidan A, Podoltsev N, Huntington S, Gore S, Davidoff A, Ma X. Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). Blood 2019, 134: 4748. DOI: 10.1182/blood-2019-128821.Peer-Reviewed Original ResearchPopulation-based studyLR-MDSMedian overall survivalOverall survivalClinical effectivenessHypomethylating agentCelgene CorporationMedian durationRed blood cellsMedian timeRing sideroblastsBoehringer IngelheimAdvisory CommitteeLarge population-based studyDaiichi SankyoOlder adultsAbnormal erythroid precursorsTransfusion independence rateEnd Results-MedicareHigh-risk MDSErythropoiesis-stimulating agentsKaplan-Meier statisticsComparative clinical effectivenessEnd of studyPart D coverage
2018
Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions
Zeidan A, Zhu W, Wang R, Stahl M, Huntington S, Giri S, Podoltsev N, Gore S, Ma X, Davidoff A. Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions. Blood 2018, 132: 838. DOI: 10.1182/blood-2018-99-116497.Peer-Reviewed Original ResearchRBC transfusion independenceHMA initiationTransfusion independenceTransfusion dependenceLR-MDSClinical trial dataHypomethylating agentTransfusion statusMedian timeMedian TI durationCox modelContinuous Medicare Parts ATrial dataRed blood cell transfusionDiagnosis of MDSRBC transfusion dependenceSubset of ptsBlood cell transfusionEnd Results-MedicareErythropoiesis-stimulating agentsHigh-risk diseaseMultivariate Cox modelTreatment of MDSEnd of studyTI durationUse of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study
Podoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Huntington S, Giri S, Davidoff A, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study. Blood 2018, 132: 4865. DOI: 10.1182/blood-2018-99-119118.Peer-Reviewed Original ResearchUse of statinsIncidence of thrombosisStatin usersLog-rank testRisk of thrombosisOverall survivalEssential thrombocythemiaET diagnosisPercentage of daysHydrophilic statinsOlder adultsET patientsMultivariate Cox proportional hazards modelLarge population-based cohort studyContinuous Medicare Parts APopulation-based cohort studyCox proportional hazards modelEnd Results-MedicareErythropoietin-independent erythroid colony formationBetter overall survivalKaplan-Meier curvesPopulation-based cohortEnd of studyProportional hazards modelPart DUse of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study
Podoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Davidoff A, Huntington S, Giri S, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. Blood 2018, 132: 3580. DOI: 10.1182/blood-2018-99-119272.Peer-Reviewed Original ResearchStatin usersImpact of statinsLog-rank testRisk of thrombosisOverall survivalPercentage of daysPV patientsMyeloproliferative neoplasmsPV diagnosisMultivariate Cox proportional hazards modelContinuous Medicare Parts ACox proportional hazards modelCardiovascular risk factorsEnd Results-MedicareErythropoietin-independent erythroid colony formationBetter overall survivalKaplan-Meier curvesType of statinPopulation-based cohortNumber of phlebotomiesEnd of studyProportional hazards modelPart DMedicare Part AHealth maintenance organizationRacial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States
Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Davidoff A, Huntington S. Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States. Blood 2018, 132: 978. DOI: 10.1182/blood-2018-99-119791.Peer-Reviewed Original ResearchSupportive care measuresMultiple myelomaInfluenza vaccinationMM therapySupportive careCare measuresFlu seasonAntiviral prophylaxisComorbidity burdenMedicare beneficiariesPre-existing chronic kidney diseaseContinuous Medicare Parts ANon-Hispanic black ethnicityMultivariable logistic regression modelRacial disparitiesHigher comorbidity burdenLower comorbidity burdenNovel MM therapiesSupportive care therapySupportive care useEnd Results-MedicareTreatment-related toxicityChronic kidney diseaseProportion of patientsYear of diagnosis
2016
Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study
Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study. The Prostate 2016, 77: 437-445. PMID: 27868212, PMCID: PMC5785924, DOI: 10.1002/pros.23281.Peer-Reviewed Original ResearchConceptsMDS/acute myeloid leukemiaAcute myeloid leukemiaProstate cancer patientsElderly prostate cancer patientsImpact of radiotherapyCancer patientsMyelodysplastic syndromeNational Cancer Institute's SurveillanceSubsequent myelodysplastic syndromeEnd Results-MedicareRetrospective cohort studyRole of radiotherapyInformed treatment decisionsUnderwent radiotherapyIMRT groupCohort studyPatient characteristicsMedian timeMyeloid leukemiaProstate cancerTreatment decisionsPatientsRadiotherapyMyeloid malignanciesSurgery
2014
Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications
Killelea BK, Long JB, Chagpar AB, Ma X, Wang R, Ross JS, Gross CP. Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications. Journal Of The National Cancer Institute 2014, 106: dju159. PMID: 25031307, PMCID: PMC4155428, DOI: 10.1093/jnci/dju159.Peer-Reviewed Original ResearchConceptsEnd Results-MedicareBreast cancer stageCohort of womenEarly-stage tumorsBreast cancer screeningAdjunct imagingSignificant changesCancer screeningCancer stageIncidence rateBreast cancerAdjunct procedureOlder womenMedicare populationMedicare beneficiariesClinical practiceComputer-aided detectionPoisson regressionNational feeCohortBreast ultrasoundWomenEarlier cohortsLater cohortsMedicare spending